1. Home
  2. EVAX
  3. EVAX News

Latest Evaxion Biotech (EVAX) News on June 7, 2025

Evaxion receives grant funding to design new polio vaccine
EVAX

GlobeNewswire

4 days ago

Evaxion receives grant funding to design new polio vaccine

EVAX

Zacks Small Cap Research

4 days ago

EVAX: Grant Illustrates Belief in Technology

EVAX

GuruFocus.com

11 days ago

Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ...

Evaxion announces business update and first quarter 2025 financial results
EVAX

GlobeNewswire

11 days ago

Evaxion announces business update and first quarter 2025 financial results

EVAX

Zacks Small Cap Research

11 days ago

EVAX Previews Exciting Year Ahead

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
EVAX

GlobeNewswire

15 days ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

EVAX

MT Newswires

16 days ago

Evaxion Biotech Doses First Patient in Extension of Cancer Vaccine Trial

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
EVAX

GlobeNewswire

16 days ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Sidoti Events, LLC's Virtual May Micro-Cap Conference
EVAX

ACCESS Newswire

18 days ago

Sidoti Events, LLC's Virtual May Micro-Cap Conference

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
EVAX

GlobeNewswire

a month ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

EVAX

Zacks Small Cap Research

a month ago

EVAX Provided Great Cancer Vaccine Update

Evaxion to present at World Vaccine Congress
EVAX

GlobeNewswire

2 months ago

Evaxion to present at World Vaccine Congress

Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement
EVAX

TipRanks

2 months ago

Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement

EVAX

GuruFocus.com

2 months ago

Evaxion Biotech AS (EVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and ...

EVAX

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Evaxion Biotech A/S Earnings Call

EVAX

Zacks Small Cap Research

2 months ago

EVAX Has Great 2024 that Sets up 2025

Evaxion announces business update and full year 2024 financial results
EVAX

GlobeNewswire

2 months ago

Evaxion announces business update and full year 2024 financial results

Evaxion to announce business update and full year 2024 financial results on April 1, 2025
EVAX

GlobeNewswire

2 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting
EVAX

GlobeNewswire

2 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion to present at numerous upcoming conferences
EVAX

GlobeNewswire

3 months ago

Evaxion to present at numerous upcoming conferences

EVAX

Zacks Small Cap Research

3 months ago

EVAX Adds to Trial Due to Excellent Results

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
EVAX

GlobeNewswire

3 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination
EVAX

GlobeNewswire

4 months ago

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion Biotech price target lowered to $6 from $35 at Lake Street
EVAX

TipRanks

4 months ago

Evaxion Biotech price target lowered to $6 from $35 at Lake Street

EVAX

Zacks Small Cap Research

4 months ago

EVAX Ups Cash to Further Research

EVAX

MT Newswires

4 months ago

Top Premarket Gainers

Evaxion announces closing of $10.8 million public offering
EVAX

GlobeNewswire

4 months ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering
EVAX

GlobeNewswire

4 months ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
EVAX

GlobeNewswire

4 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
EVAX

Clinical Trials Arena

5 months ago

Evaxion concludes subject dosing in Phase II trial of melanoma vaccine

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
EVAX

GlobeNewswire

5 months ago

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01

EVAX

Zacks Small Cap Research

5 months ago

EVAX Adjusts Share Ratio

Evaxion announces completion of ADS ratio change
EVAX

GlobeNewswire

5 months ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
EVAX

GlobeNewswire

5 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change
EVAX

GlobeNewswire

5 months ago

Evaxion announces plan to implement ADS ratio change

Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
EVAX

GlobeNewswire

6 months ago

Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity

Evaxion establishes new AI-derived precision cancer vaccine concept
EVAX

GlobeNewswire

6 months ago

Evaxion establishes new AI-derived precision cancer vaccine concept

Evaxion announces 2025 milestones reflecting continued strong strategy execution
EVAX

GlobeNewswire

6 months ago

Evaxion announces 2025 milestones reflecting continued strong strategy execution

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
EVAX

GlobeNewswire

6 months ago

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress

Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
EVAX

GlobeNewswire

7 months ago

Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing

EVAX

Zacks Small Cap Research

7 months ago

EVAX Racks up Positive Test Results

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
EVAX

GlobeNewswire

7 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results
EVAX

GlobeNewswire

7 months ago

Evaxion announces business update and third quarter 2024 financial results

EVAX

Zacks Small Cap Research

7 months ago

EVAX Exceeds Estimates and Confirms Partnership

Evaxion to announce business update and third quarter 2024 financial results on October 31
EVAX

GlobeNewswire

7 months ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

EVAX

Zacks Small Cap Research

8 months ago

OTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCR

Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
EVAX

GlobeNewswire

8 months ago

Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials

Evaxion Biotech Charts Future with Innovative Immune Therapies
EVAX

TipRanks

8 months ago

Evaxion Biotech Charts Future with Innovative Immune Therapies

EVAX

Zacks Small Cap Research

8 months ago

AI from EVAX Improves Trial Results

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
EVAX

GlobeNewswire

8 months ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

EVAX

MT Newswires

8 months ago

Evaxion Biotech Grants Merck Option to License Vaccine Candidates

Evaxion significantly expands vaccine development collaboration with MSD
EVAX

GlobeNewswire

8 months ago

Evaxion significantly expands vaccine development collaboration with MSD

EVAX

Zacks Small Cap Research

8 months ago

EVAX Process Continues to Garner Interest and Investment

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
EVAX

GlobeNewswire

9 months ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
EVAX

GlobeNewswire

9 months ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Life Sciences Virtual Investor Forum Agenda Announced for September 19th
EVAX

GlobeNewswire

9 months ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
EVAX

GlobeNewswire

9 months ago

Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01

Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
EVAX

GlobeNewswire

9 months ago

Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
EVAX

GlobeNewswire

9 months ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

EVAX

Zacks Small Cap Research

9 months ago

EVAX Uses AI Platform to Generate Positive Treatment Data

Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near?
EVAX

Simply Wall St.

9 months ago

Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near?

EVAX

Zacks Small Cap Research

10 months ago

EVAX is a Clinical Stage AI Company Worth a Look

Evaxion Announces Business Update and Second Quarter 2024 Financial Results
EVAX

GlobeNewswire

10 months ago

Evaxion Announces Business Update and Second Quarter 2024 Financial Results

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
EVAX

GlobeNewswire

10 months ago

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
EVAX

GlobeNewswire

10 months ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

EVAX

Zacks Small Cap Research

10 months ago

EVAX: Initiating Coverage of Evaxion

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
EVAX

GlobeNewswire

a year ago

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
EVAX

GlobeNewswire

a year ago

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
EVAX

GlobeNewswire

a year ago

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
EVAX

GlobeNewswire

a year ago

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
EVAX

Zacks

a year ago

Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now

Lotto 6/49 - $64 million up for grabs in the next draw!
EVAX

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
EVAX

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
EVAX

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
EVAX

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
EVAX

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
EVAX

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
EVAX

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
EVAX

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
EVAX

GlobeNewswire

a year ago

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Evaxion Announces Business Update and First Quarter 2024 Financial Results
EVAX

GlobeNewswire

a year ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

EVAX

MT Newswires

a year ago

Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
EVAX

GlobeNewswire

a year ago

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Receives Nasdaq Notification
EVAX

GlobeNewswire

a year ago

Evaxion Receives Nasdaq Notification

Sidoti Events, LLC's Virtual May Micro-Cap Conference
EVAX

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
EVAX

GlobeNewswire

a year ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
EVAX

Zacks

a year ago

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
EVAX

Insider Monkey

a year ago

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
EVAX

GlobeNewswire

a year ago

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion Announces Business Update and Full Year 2023 Financial Results
EVAX

GlobeNewswire

a year ago

Evaxion Announces Business Update and Full Year 2023 Financial Results

When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?
EVAX

Simply Wall St.

a year ago

When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
EVAX

GlobeNewswire

a year ago

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
EVAX

GlobeNewswire

a year ago

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
EVAX

GlobeNewswire

a year ago

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
EVAX

GlobeNewswire

a year ago

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion Announces Closing of $15 Million Public Offering
EVAX

GlobeNewswire

a year ago

Evaxion Announces Closing of $15 Million Public Offering

Evaxion Biotech Announces Pricing of $15 Million Public Offering
EVAX

GlobeNewswire

a year ago

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
EVAX

GlobeNewswire

a year ago

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Western New England Bancorp, Inc. Reports Results for Three Months and Year Ended December 31, 2023 and Declares Quarterly Cash Dividend
EVAX

GlobeNewswire

a year ago

Western New England Bancorp, Inc. Reports Results for Three Months and Year Ended December 31, 2023 and Declares Quarterly Cash Dividend

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
EVAX

GlobeNewswire

a year ago

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Share on Social Networks: